Inga Jessen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Inga Jessen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Jakob Liermann
Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
2 shared publications - Jürgen Debus
Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany
2 shared publications Amir Abdollahi
National Center for Tumor Diseases (NCT), Heidelberg, Germany; Heidelberg Ion Beam Therapy Center (HIT), Heidelberg, Germany; German Cancer Research Center (DKFZ), Clinical Cooperation Unit Radiation Oncology, Heidelberg, Germany; German Cancer Consortium (DKTK), Partner Site Heidelberg, Heidelberg, Germany
1 shared publicationAndrea Mairani
Heidelberg Ion Beam Therapy Center (HIT), Heidelberg, Germany; German Cancer Research Center (DKFZ), Clinical Cooperation Unit Radiation Oncology, Heidelberg, Germany; Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy
1 shared publicationBeata Koczur
Heidelberg Ion Beam Therapy Center (HIT), Heidelberg, Germany
1 shared publicationBouchra Tawk
Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany; German Cancer Research Center (DKFZ), Clinical Cooperation Unit Radiation Oncology, Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226, 111836
Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268)
- 22 October 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 226, 111836
Open AccessCarbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268)
- Open Access
Clinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution
(1) Background: Recent publications foster stereotactic body radiotherapy (SBRT) in patients with adrenal oligometastases or oligoprogression. However, local control (LC) after non-adaptive SBRT shows the potential for improvement. Online adaptive MR-guided SBRT (MRgSBRT) improves tumor coverage and organ-at-risk (OAR) sparing. Long-term results of adaptive MRgSBRT are still sparse. (2) Methods: Adaptive MRgSBRT was performed on a 0.35 T MR-Linac. LC, overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity were assessed. (3) Results: 35 patients with 40 adrenal metastases were analyzed. The median gross tumor volume was 30.6 cc. The most common regimen was 10 fractions at 5 Gy. The median biologically effective dose (BED10) was 75.0 Gy. Plan adaptation was performed in 98% of all fractions. The median follow-up was 7.9 months. One local failure occurred after 16.6 months, resulting in estimated LC rates of 100% at one year and 90% at two years. ORR was 67.5%. The median OS was 22.4 months, and the median PFS was 5.1 months. No toxicity > CTCAE grade 2 occurred. (4) Conclusions: LC and ORR after adrenal adaptive MRgSBRT were excellent, even in a cohort with comparably large metastases. A BED10 of 75 Gy seems sufficient for improved LC in comparison to non-adaptive SBRT.
Open AccessClinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution
(1) Background: Recent publications foster stereotactic body radiotherapy (SBRT) in patients with adrenal oligometastases or oligoprogression. However, local control (LC) after non-adaptive SBRT shows the potential for improvement. Online adaptive MR-guided SBRT (MRgSBRT) improves tumor coverage and organ-at-risk (OAR) sparing. Long-term results of adaptive MRgSBRT are still sparse. (2) Methods: Adaptive MRgSBRT was performed on a 0.35 T MR-Linac. LC, overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity were assessed. (3) Results: 35 patients with 40 adrenal metastases were analyzed. The median gross tumor volume was 30.6 cc. The most common regimen was 10 fractions at 5 Gy. The median biologically effective dose (BED10) was 75.0 Gy. Plan adaptation was performed in 98% of all fractions. The median follow-up was 7.9 months. One local failure occurred after 16.6 months, resulting in estimated LC rates of 100% at one year and 90% at two years. ORR was 67.5%. The median OS was 22.4 months, and the median PFS was 5.1 months. No toxicity > CTCAE grade 2 occurred. (4) Conclusions: LC and ORR after adrenal adaptive MRgSBRT were excellent, even in a cohort with comparably large metastases. A BED10 of 75 Gy seems sufficient for improved LC in comparison to non-adaptive SBRT.